A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.
The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.
An updated analysis from the GioTag study supports the rationale for giving Gilotrif followed by Tagrisso in patients with EGFR Del19-positive lung cancer.
Instead of trying to tackle resistance by targeting rare mutations, researchers are looking to antibody based therapies that are more broadly active in lung cancer patients.
New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.
